Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CITADEL-123: A Phase I clinical trial to assess the activity of I-123 Poly Adenosine Diphosphate Ribose Polymerase I inhibitor (123I-ATT001) directly administered in subjects with relapsed glioblastoma

Next Previous
Trial Profile

CITADEL-123: A Phase I clinical trial to assess the activity of I-123 Poly Adenosine Diphosphate Ribose Polymerase I inhibitor (123I-ATT001) directly administered in subjects with relapsed glioblastoma

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 24 Oct 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ATT-001 (Primary) ; Antineoplastics
  • Indications Glioblastoma
  • Focus Adverse reactions; First in man
  • Acronyms CITADEL-123
  • Sponsors Ariceum Therapeutics; Theragnostics

Most Recent Events

  • 25 Jul 2024 According to an Ariceum Therapeutics media release, Dr Paul Mulholland, UCLH consultant medical oncologist, is the chief investigator of the study.
  • 25 Jul 2024 According to an Ariceum Therapeutics media release, trial opened at University College London Hospitals (UCLH) and will assess the safety and early efficacy of 123I-ATT001.
  • 25 Jul 2024 According to an Ariceum Therapeutics media release, company has commenced a Phase 1 first-in-human clinical trial (CITADEL-123) of 123I-ATT001, in patients with recurrent glioblastoma.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top